Send to

Choose Destination
See comment in PubMed Commons below
Mediterr J Hematol Infect Dis. 2012;4(1):e2012035. doi: 10.4084/MJHID.2012.035. Epub 2012 May 7.

Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis.

Author information

Hematology, "Sapienza" University of Rome. Via Benevento 6, 00161 Rome (Italy).



Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).


We used Bortezomib without corticosteroids, to avoid the risk of lung infection reactivations due to patient's Pseudomonas aeruginosa colonization, in a MM patient with Cystic Fibrosis. Four 21-day cycles of Bortezomib were administrated at 1.3 mg/m(2) on days 1,4,8 and 11 with a 10 day rest period. Treatment response and toxicity were evaluated.


After four cycles of therapy the patient achieved a very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.


Bortezomib can be successfully utilized for the management of this difficult disease situation.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Catholic University in Rome, Institute of Hematology Icon for PubMed Central
    Loading ...
    Support Center